$16.64
0[0.00%]
At close: May 2
$16.64
0[0.00%]
PreMarket: 4:00PM EDT
Regenxbio
(NASDAQ:RGNX)Latest News for Regenxbio Stock (NASDAQ:RGNX)
Regenxbio Stock (NASDAQ: RGNX)
Categories: All
Friday, April 12, 2024
Thursday, March 28, 2024
Monday, March 25, 2024
Monday, March 11, 2024
Friday, March 08, 2024
- This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIOVandana Singh - Mar 8, 2024, 1:43PM
- Regenxbio shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $20 to $35.Benzinga Newsdesk - Mar 8, 2024, 8:48AM
- RBC Capital Upgrades Regenxbio to Outperform, Raises Price Target to $35Benzinga Newsdesk - Mar 8, 2024, 7:59AM
Thursday, March 07, 2024
- Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price TargetBenzinga Newsdesk - Mar 7, 2024, 9:45AM
- Barclays Maintains Overweight on Regenxbio, Raises Price Target to $55Benzinga Newsdesk - Mar 7, 2024, 7:16AM
- REGENXBIO Prices Upsized Public Offering Of 4,565,260 Common Shares At $23/Share And 1,521,740 Pre-Funded Warrants At $22.9999/WarrantBenzinga Newsdesk - Mar 7, 2024, 2:44AM
Wednesday, March 06, 2024
- REGENXBIO Announces Proposed $125M Public Offering Of Common StockBenzinga Newsdesk - Mar 6, 2024, 4:30PM
- Leerink Partners Upgrades Regenxbio to OutperformBenzinga Newsdesk - Mar 6, 2024, 9:33AM
- Beyond The Numbers: 4 Analysts Discuss Regenxbio StockBenzinga Insights - Mar 6, 2024, 8:00AM
- Baird Maintains Outperform on Regenxbio, Raises Price Target to $39Benzinga Newsdesk - Mar 6, 2024, 7:55AM
Tuesday, March 05, 2024
- REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock SoarsVandana Singh - Mar 5, 2024, 12:07PM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Mar 5, 2024, 8:09AM
- REGENXBIO shares are trading higher after the company announced new initial efficacy data from its AFFINITY DUCHENNE trial of RGX-202.Benzinga Newsdesk - Mar 5, 2024, 7:36AM
- Regenxbio Announces New Initial Efficacy Data From Affinity Duchenne TrialBenzinga Newsdesk - Mar 5, 2024, 7:07AM
Friday, March 01, 2024
Wednesday, February 28, 2024
Tuesday, February 27, 2024
- REGENXBIO Expects Its Balance In Cash & Equivalents Of $314.1M As Of December 31, 2023 To Fund Its Operations Into H2 Of 2025Benzinga Newsdesk - Feb 27, 2024, 4:49PM
- Regenxbio: Q4 Earnings InsightsBenzinga Insights - Feb 27, 2024, 4:15PM
- Regenxbio Q4 2023 GAAP EPS $(1.43) Misses $(1.27) Estimate, Sales $22.21M Miss $34.00M EstimateBenzinga Newsdesk - Feb 27, 2024, 4:11PM
- Earnings Scheduled For February 27, 2024Benzinga Insights - Feb 27, 2024, 5:01AM
Monday, February 26, 2024
Wednesday, February 21, 2024
Monday, February 12, 2024
Thursday, February 08, 2024
Wednesday, February 07, 2024
- Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Feb 7, 2024, 1:02PM
- Why Is Gene Therapy-Focused REGENXBIO Stock Trading Higher Today?Vandana Singh - Feb 7, 2024, 12:59PM
- REGENXBIO shares are trading higher after the company announced that its pivotal trial of RGX-121 for the treatment of MPS II achieved its primary endpoint.Benzinga Newsdesk - Feb 7, 2024, 12:15PM
- REGENXBIO Says As Of January 3, 2024, RGX-121 Continues To Be Well Tolerated In 25 Patients Dosed Across All Phases Of Campsiite TrialBenzinga Newsdesk - Feb 7, 2024, 11:44AM
- REGENXBIO Announces Pivotal Trial Of RGX-121 For The Treatment Of MPS II Achieves Primary EndpointBenzinga Newsdesk - Feb 7, 2024, 11:42AM
- Chipotle Posts Upbeat Earnings, Joins Cirrus Logic, Emerson Electric, Carlyle Group And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - Feb 7, 2024, 11:38AM
- Regenxbio Has Completed Enrollment At Dose Level 2 And Reported Additional Interim Safety And Efficacy In Phase 1/2 AFFINITY DUCHENNE Trial Of Rgx-202 In Patients With Duchenne Muscular Dystrophy Ages 4 To11 Years OldBenzinga Newsdesk - Feb 7, 2024, 7:14AM
Wednesday, January 17, 2024
- Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal ThicknessVandana Singh - Jan 17, 2024, 3:28PM
- Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market SessionAvi Kapoor - Jan 17, 2024, 5:32AM
Tuesday, January 16, 2024
Monday, January 08, 2024
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Jan 8, 2024, 1:36PM
- REGENXBIO shares are trading lower after the U.S. District Court issued a decision for the company's and the University of Pennsylvania's NAV Technology Platform patent infringement lawsuit.Benzinga Newsdesk - Jan 8, 2024, 12:20PM
- Boeing, Pacific Biosciences of California And Other Big Stocks Moving Lower On MondayAvi Kapoor - Jan 8, 2024, 11:46AM
- US District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV Technology Patent Infringement LawsuitBenzinga Newsdesk - Jan 8, 2024, 7:27AM
Wednesday, November 29, 2023
Wednesday, November 08, 2023
- REGENXBIO Anticipates Total Savings Of At Least $100M Over Next Two Years; Anticipated Cost Savings Along With $365M In Cash, Cash Equivalents And Marketable Securities Expected To Fund Operations Into H2 2025Benzinga Newsdesk - Nov 8, 2023, 5:54PM
- Regenxbio Q3 2023 Gaap EPS $(1.41) Beats $(1.49) Estimate, Sales $28.91M Beat $27.19M EstimateBenzinga Newsdesk - Nov 8, 2023, 4:57PM
- Earnings Scheduled For November 8, 2023Benzinga Insights - Nov 8, 2023, 4:21AM